No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LIPO Lipella Pharmaceuticals
- 0.523
- +0.016+3.14%
Trading Jul 11 13:18 ET
3.97MMarket Cap-706P/E (TTM)
0.575High0.490Low115.15KVolume0.483Open0.507Pre Close60.15KTurnover2.40%Turnover RatioLossP/E (Static)7.61MShares2.71052wk High1.55P/B2.51MFloat Cap0.40052wk Low--Dividend TTM4.81MShs Float7.720Historical High--Div YieldTTM16.78%Amplitude0.400Historical Low0.522Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Lipella Pharmaceuticals Completes Site Initiation Visit For Phase 2a Trial Of LP-310 In Oral Lichen Planus; Clinical Testing Of LP-310 Expected To Commence In Mid 2024
Express News | Lipella Pharmaceuticals Inc -Study Is Anticipated to Conclude in Mid-2025
Express News | Lipella Pharmaceuticals Inc -Patient Recruitment Is Underway for Phase 2a Multicenter, Dose-Ranging Study
Express News | Lipella Pharmaceuticals Inc - Clinical Testing of LP-310 Expected to Commence in Mid-2024
Express News | Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Comments
$Lipella Pharmaceuticals(LIPO.US$
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evalua...
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evalua...
1
$Lipella Pharmaceuticals(LIPO.US$ Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
1
1
$Lipella Pharmaceuticals(LIPO.US$ 10% Shareholder Kaufman Jonathan H purchased 55,000 shares of Common Stocks on Mar 18, 19, 2024 at an average price of $0.8264 for a total value of $45,451.5.
1
13
2
2
$Lipella Pharmaceuticals(LIPO.US$ Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
3 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
3 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
